Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

August 14, 2024

https://www.globenewswire.com/news-release/2024/08/14/2929913/0/en/Neumora-Therapeutics-to-Host-Key-Opinion-Leader-Roundtable-to-Discuss-the-Potential-of-Navacaprant-in-Neuropsychiatric-Disorders.html

WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will host a roundtable discussion on the neuropsychiatric treatment landscape and role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The discussion will feature leading experts in neuropsychiatry and will take place on Thursday, September 12 at 8:00 a.m. ET.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.